Genmab throws in the towel – won't contest royalties ruling
The Danish biotech firm won’t be seeking a review of its arbitration case against Janssen, which Genmab lost at the beginning of April.
by andreas lønstrup, translated by daniel pedersen
Genmab has decided to let the royalties dispute over multiple myeloma treatment Darzalex with its collaboration partner Janssen lie.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab loses royalties case against Janssen
For subscribers
